Hormone Therapy-Related Hot Flashes Tied to Worse Breast Cancer Outcomes
Breast cancer patients who used drugs for hot flashes shortly after starting adjuvant hormone therapy had worse disease-free survival.
Breast Cancer
US Is Home to More Than 18 Million Cancer Survivors
There were more than 18 million cancer survivors in the United States at the beginning of this year, according to new data.
Exercise Improves Global Longitudinal Strain in Breast Cancer Survivors
Higher physical activity levels are associated with improved global longitudinal strain in breast cancer survivors.
Factors ID’d in Time to Breast Biopsy by Race, Ethnicity
White women were more likely than Asian, Black, and Hispanic women to have a biopsy within 30 days or 60 days of an abnormal result.
Men With Breast Cancer Present at Later Stage, Have Worse Prognosis Than Women
At 10 years, the disease-free survival rate was 54.5%, and the overall survival rate was 50.7%.
Denosumab Improves Long-Term Outcomes in AI-Treated Breast Cancer
Patients who received denosumab had a significant improvement in disease-free survival and bone metastasis-free survival.
Age, Follow-Up Interval Associated With Risk of Breast Cancer-Related Lymphedema After Axillary Lymph Node Dissection
Researchers sought to identify factors that increase the risk of developing breast cancer-related lymphedema in patients who underwent axillary lymph node dissection.
Prevalence of Cancer Among Pregnant Patients on the Rise
The prevalence of pregnancy with cancer increased 13.8% from 2016 to 2019.
Nab-Paclitaxel Plus Pembrolizumab in HR+ Breast Cancer
Researchers are conducting a phase 1 trial of nab-paclitaxel and pembrolizumab in patients with hormone receptor-positive breast cancer.
RGT-419B Alone or With Hormone Therapy in HR+/HER2- Advanced Breast Cancer
Researchers are conducting a phase 1 trial to evaluate RGT-419B, a CDK2/4/6 inhibitor, in patients with HR+, HER2-, stage III/IV breast cancer.
- Loading...
Loading...
Next post in Breast Cancer
Loading... 
Loading...